CXCR2 and neoplasm: Patients exhibiting an enrichment of innate immune cells within the TME may respond positively to myeloid-targeted therapies such as C-X-C motif chemokine receptor 2 (CXCR2) and colony-stimulating factor receptor (CSFR) inhibitors, which aim to deplete or reprogram tumor-associated neutrophils (58, 59).